Physician profile
Usman Ajaz
NPI 1912261025
$10,839.12
in general payments reported to CMS, 2019-2025
35 companies · $1,825 in 2025
The $1,825 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $303 · 2021: $975 · 2022: $1,457 · 2023: $1,721 · 2024: $3,140 · 2025: $1,825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,961 · Consulting Fee: $1,680 · Travel and Lodging: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,960.69 |
| Consulting Fee | $1,680.00 |
| Travel and Lodging | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,796.50 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $1,779.72 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $1,624.51 | 2019-2025 | Rinvoq |
| Lilly USA, LLC | $594.86 | 2019-2025 | Olumiant, Zepbound, Taltz |
| Pfizer INC. | $502.82 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $429.42 | 2019-2023 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $420.14 | 2022-2025 | Saphnelo, Farxiga |
| Glaxosmithkline, LLC. | $386.84 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $384.46 | 2019-2025 | |
| Ucb, INC. | $320.69 | 2020-2025 | Bimzelx |
| Ani Pharmaceuticals, INC. | $169.29 | 2022-2023 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $166.71 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $153.46 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.12 | 2022-2023 | Jardiance, Cyltezo |
| Genentech USA, INC. | $139.85 | 2019-2025 | Actemra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $124.37 | 2019 | |
| Alexion Pharmaceuticals, INC. | $122.84 | 2019 | |
| Novo Nordisk INC | $87.22 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $70.83 | 2024-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $48.46 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.41 | 2021-2024 | |
| Recordati_rare_diseases_inc. | $37.97 | 2023-2024 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $33.30 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Chiesi USA, INC. | $31.96 | 2024 | Mycapssa |
| Biomarin Pharmaceutical INC. | $30.22 | 2023 | Palynziq |
| Sobi, INC | $26.38 | 2019 | |
| Ascensia Diabetes Care US INC. | $24.96 | 2023 | |
| Corcept Therapeutics | $23.98 | 2023 | Korlym |
| Teva Pharmaceuticals USA, INC. | $20.86 | 2021 | |
| Urgo Medical North America, LLC | $20.02 | 2025 | Urgoclean Ag |
| Otsuka America Pharmaceutical, INC. | $17.34 | 2019 | |
| Genzyme Corporation | $17.19 | 2024 | |
| Cequr Corporation | $16.50 | 2024 | Cequr Simplicity |
| Convatec INC. | $14.86 | 2025 | |
| Radius Health, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Ajaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.